دورية أكاديمية
A prediction model for response to immune checkpoint inhibition in advanced melanoma.
| العنوان: | A prediction model for response to immune checkpoint inhibition in advanced melanoma. |
|---|---|
| المؤلفون: | van Duin IAJ; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., Verheijden RJ; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., van Diest PJ; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., Blokx WAM; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., El-Sharouni MA; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., Verhoeff JJC; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., Leiner T; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA., van den Eertwegh AJM; Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands., de Groot JWB; Isala Oncology Center, Zwolle, The Netherlands., van Not OJ; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, The Netherlands., Aarts MJB; Department of Medical Oncology, GROW-School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands., van den Berkmortel FWPJ; Department of Medical Oncology, Zuyderland Medical Centre Sittard, Sittard-Geleen, The Netherlands., Blank CU; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Haanen JBAG; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Hospers GAP; Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands., Piersma D; Department of Internal Medicine, Medisch Spectrum Twente, Enschede, The Netherlands., van Rijn RS; Department of Internal Medicine, Medical Centre Leeuwarden, Leeuwarden, The Netherlands., van der Veldt AAM; Department of Medical Oncology and Radiology & Nuclear Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands., Vreugdenhil G; Department of Internal Medicine, Maxima Medical Centre, Eindhoven, The Netherlands., Wouters MWJM; Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, The Netherlands.; Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, The Netherlands.; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Stevense-den Boer MAM; Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands., Boers-Sonderen MJ; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands., Kapiteijn E; Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands., Suijkerbuijk KPM; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., Elias SG; Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. |
| المصدر: | International journal of cancer [Int J Cancer] 2024 May 15; Vol. 154 (10), pp. 1760-1771. Date of Electronic Publication: 2024 Jan 31. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0215 (Electronic) Linking ISSN: 00207136 NLM ISO Abbreviation: Int J Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 1995- : New York, NY : Wiley-Liss Original Publication: 1966-1984 : Genève : International Union Against Cancer |
| مواضيع طبية MeSH: | Melanoma*/pathology , Skin Neoplasms*/pathology, Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Ipilimumab/therapeutic use ; Nivolumab/therapeutic use ; Retrospective Studies |
| مستخلص: | Predicting who will benefit from treatment with immune checkpoint inhibition (ICI) in patients with advanced melanoma is challenging. We developed a multivariable prediction model for response to ICI, using routinely available clinical data including primary melanoma characteristics. We used a population-based cohort of 3525 patients with advanced cutaneous melanoma treated with anti-PD-1-based therapy. Our prediction model for predicting response within 6 months after ICI initiation was internally validated with bootstrap resampling. Performance evaluation included calibration, discrimination and internal-external cross-validation. Included patients received anti-PD-1 monotherapy (n = 2366) or ipilimumab plus nivolumab (n = 1159) in any treatment line. The model included serum lactate dehydrogenase, World Health Organization performance score, type and line of ICI, disease stage and time to first distant recurrence-all at start of ICI-, and location and type of primary melanoma, the presence of satellites and/or in-transit metastases at primary diagnosis and sex. The over-optimism adjusted area under the receiver operating characteristic was 0.66 (95% CI: 0.64-0.66). The range of predicted response probabilities was 7%-81%. Based on these probabilities, patients were categorized into quartiles. Compared to the lowest response quartile, patients in the highest quartile had a significantly longer median progression-free survival (20.0 vs 2.8 months; P < .001) and median overall survival (62.0 vs 8.0 months; P < .001). Our prediction model, based on routinely available clinical variables and primary melanoma characteristics, predicts response to ICI in patients with advanced melanoma and discriminates well between treated patients with a very good and very poor prognosis. (© 2024 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.) |
| References: | Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol. 2022;40(2):127-137. doi:10.1200/JCO.21.02229. van Not OJ, Blokx WAM, van den Eertwegh AJM, et al. BRAF and NRAS mutation status and response to checkpoint inhibition in advanced melanoma. JCO Precis Oncol. 2022;6:e2200018. doi:10.1200/PO.22.00018. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158-168. doi:10.1056/NEJMra1703481. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34. doi:10.1056/NEJMoa1504030. Franken MG, Leeneman B, Aarts MJB, et al. Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs. ESMO Open. 2021;6(6):100320. doi:10.1016/j.esmoop.2021.100320. ter Maat LS, van Duin IAJ, Elias SG, et al. Imaging to predict checkpoint inhibitor outcomes in cancer. A systematic review. Eur J Cancer. 1990;2022(175):60-76. doi:10.1016/j.ejca.2022.07.034. Weide B, Martens A, Hassel JC, et al. Baseline biomarkers for outcome of melanoma patients treated with Pembrolizumab. Clin Cancer Res. 2016;22(22):5487-5496. doi:10.1158/1078-0432.CCR-16-0127. Jessurun CAC, Vos JAM, Limpens J, Luiten RM. Biomarkers for response of melanoma patients to immune checkpoint inhibitors: a systematic review. Front Oncol. 2017;7:233. van Zeijl MCT, Haanen JBAG, Wouters MWJM, et al. Real-world outcomes of first-line anti-PD-1 therapy for advanced melanoma: a nationwide population-based study. J Immunother. 2020;43(8):256-264. doi:10.1097/CJI.0000000000000334. Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018;19(5):672-681. doi:10.1016/S1470-2045(18)30139-6. Pires da Silva I, Ahmed T, McQuade JL, et al. Clinical models to define response and survival with anti-PD-1 antibodies alone or combined with ipilimumab in metastatic melanoma. J Clin Oncol. 2022;40(10):1068-1080. doi:10.1200/JCO.21.01701. Nosrati A, Tsai KK, Goldinger SM, et al. Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. Br J Cancer. 2017;116(9):1141-1147. doi:10.1038/bjc.2017.70. van Not OJ, de Meza MM, van den Eertwegh AJM, et al. Response to immune checkpoint inhibitors in acral melanoma: a nationwide cohort study. Eur J Cancer. 2022;167:70-80. doi:10.1016/j.ejca.2022.02.026. Rauwerdink DJW, van Doorn R, van der Hage J, et al. Systemic therapy in advanced nodular melanoma versus superficial spreading melanoma: a nation-wide study of the Dutch Melanoma Treatment Registry. Cancer. 2022;14(22):5694. doi:10.3390/cancers14225694. Mao L, Qi Z, Zhang L, Guo J, Si L. Immunotherapy in acral and mucosal melanoma: current status and future directions. Front Immunol. 2021;12:680407. doi:10.3389/fimmu.2021.680407. Jochems A, Schouwenburg MG, Leeneman B, et al. Dutch Melanoma Treatment Registry: quality assurance in the care of patients with metastatic melanoma in The Netherlands. Eur J Cancer. 1990;2017(72):156-165. doi:10.1016/j.ejca.2016.11.021. Moons KGM, Altman DG, Reitsma JB, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162(1):W1-W73. doi:10.7326/M14-0698. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472-492. doi:10.3322/caac.21409. van Duin IAJ, Elias SG, van den Eertwegh AJM, et al. Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma. Int J Cancer. 2023;152:2493-2502. doi:10.1002/ijc.34479. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247. doi:10.1016/j.ejca.2008.10.026. Riley RD, Snell KI, Ensor J, et al. Minimum sample size for developing a multivariable prediction model: PART II-binary and time-to-event outcomes. Stat Med. 2019;38(7):1276-1296. doi:10.1002/sim.7992. Wensink GE, Bolhuis K, Elferink MAG, et al. Predicting early extrahepatic recurrence after local treatment of colorectal liver metastases. Br J Surg. 2023;110(3):362-371. doi:10.1093/bjs/znac461. Robert C, Long GV, Brady B, et al. Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma. J Clin Oncol. 2020;38(33):3937-3946. doi:10.1200/JCO.20.00995. van der Kooij MK, Joosse A, Suijkerbuijk KPM, et al. Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study. Br J Cancer. 2022;128:1-4. doi:10.1038/s41416-022-02088-8. |
| معلومات مُعتمدة: | 848101007 Netherlands ZONMW_ ZonMw |
| فهرسة مساهمة: | Keywords: immune checkpoint inhibition; immunotherapy; melanoma; prediction model; response prediction |
| المشرفين على المادة: | 0 (Immune Checkpoint Inhibitors) 0 (Ipilimumab) 31YO63LBSN (Nivolumab) |
| تواريخ الأحداث: | Date Created: 20240131 Date Completed: 20240314 Latest Revision: 20240314 |
| رمز التحديث: | 20240314 |
| DOI: | 10.1002/ijc.34853 |
| PMID: | 38296842 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1097-0215 |
|---|---|
| DOI: | 10.1002/ijc.34853 |